Current and future perspectives on the management of polypharmacy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Because of ageing populations, the growth in the number of people with multi-morbidity and greater compliance with disease-specific guidelines, polypharmacy is becoming increasingly common. Although the correct drug treatment in patients with complex medical problems can improve clinical outcomes, quality of life and life expectancy, polypharmacy is also associated with an increased risk of adverse drug events, some severe enough to result in hospital admission and even death. Hence, having systems in place to ensure that medications are started only when there is a suitable indication, ensuring patients are fully aware of the benefits and complications that may arise from their treatment, and reviewing patients regularly to ensure their medication regime remains appropriate, are essential. DISCUSSION: The development and rapid uptake of electronic patient records - particularly in primary care settings where the majority of prescribing takes place - makes monitoring of patients more straightforward than in the past; and allows identification of sub-groups of patients at particularly high risk of adverse drug events and complications. It also facilitates 'deprescribing' the process by which medications are reviewed and stopped if not clinically beneficial. In recent years, we have also seen the development of smartphone 'apps' to improve communication between patients and healthcare professionals, improve people's understanding of their conditions and their treatment, and maintain a record of changes made to patient's medication. In the longer term, developments such as the introduction of artificial intelligence and clinical decision support systems also have the potential to improve prescribing and minimise the risks from polypharmacy. Finally, there is considerable scope to improve the quality of prescribing and reduce risks from poly-pharmacy using non-medical groups such as pharmacists, specialist nurses and physician assistants. Polypharmacy has increased in recent decades and will continue to increase as populations age and the number of people with multiple long-term conditions increases. As with all areas of medicine, the evidence-base in this area continues to evolve. Further trials on the impact on patients with polypharmacy of new interventions such as technology-based solutions and the use of different professional groups are needed to improve the evidence-base in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mastering the game of Go with deep neural networks and tree search
Silver, D., Huang, A., Maddison, C. J., Guez, A., Sifre, L., van den Driessche, G., Schrittwieser, J., Antonoglou, I., Panneershelvam, V., Lanctot, M., et al. (2016) · Nature · doi:10.1038/nature16961 · Cited by 15,612
Predicting the future - big data, machine learning, and clinical medicine
Obermeyer, Z., & Emanuel, E. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606181 · Cited by 3,652 · cited 1×
“their clinical teams the option to modify their patients’ treatment to reduce this excess risk [37].”
BackgroundShared decision making — The pinnacle of patient-centered care
Barry, M. J., & Edgman-Levitan, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1109283 · Cited by 3,433 · cited 2×
“A physician-targeted educational session in the USA improved the content of and enhanced patient ratings of physician communication about new medication prescriptions [42].”
MethodBy the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., & Brindle, P. (2008) · BMJ · doi:10.1136/bmj.39609.449676.25 · Cited by 1,459 · cited 1×
“cular risk, such as QRISK in the UK [23, 24].”
BackgroundThe Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview
Black, A. D., Car, J., Pagliari, C., Anandan, C., Cresswell, K., Bokun, T., McKinstry, B., Procter, R., Majeed, A., & Sheikh, A. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000387 · Cited by 1,442
Self-citationMay, C. R., Eton, D. T., Boehmer, K., Gallacher, K., Hunt, K., MacDonald, S., Mair, F. S., May, C. M., Montori, V. M., Richardson, A., et al. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-281 · Cited by 720 · cited 1×
“can also help approve patient’s adherence to their medication [47].”
BackgroundThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646 · cited 1×
“New smartphone applications aimed at patients with long-term conditions have the potential to help in the recording and management of drug sideeffects but their use requires further evaluation [43]; as do systems for allowing patients to self-report drug side effects to national pharmaceutical regulatory organisations…”
Background
Cited by
Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences
Pazan, F., & Wehling, M. (2021) · European Geriatric Medicine · doi:10.1007/s41999-021-00479-3 · Cited by 542
Metadata
- Authors
- Molokhia, M., & Majeed, A.
- Venue
- BMC Family Practice
- Published
- 2017-06-06
- Volume
- 18
- Issue
- 1
- Pages
- 70-70
- ISSN
- 1471-2296 (ISSN-L)
- OpenAlex
- W2622629370
- Cited by
- 175
- References
- 8
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and future perspectives on the management of polypharmacy. https://app.cochat.ai/papers/10.1186/s12875-017-0642-0
- The paper
- Molokhia, M., & Majeed, A. (2017). Current and future perspectives on the management of polypharmacy. BMC Family Practice. https://doi.org/10.1186/s12875-017-0642-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.